Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study

Conclusions Although the presence of severe comorbidities was lower when assessed by ACE-27 (13%) compared to HCT-CI (23%), and the spectrums of comorbidities captured were different, the overall impact of severe comorbidities as assessed by both scales appears to be similar and associated with a survival disadvantage. Teaser In a retrospective study of 309 patients with myelofibrosis (MF), severe burden of comorbidities as assessed by the Adult Comorbidity Evaluation 27 (ACE-27) or Hematopoietic Cell Transplant Comorbidity Index (HCT-CI) was associated with worse overall survival. ACE-27 may be preferred for comorbidity assessment in myeloproliferative neoplasm (MPN) patients as it captures cardiovascular and venous thrombosis related morbidities better than HCT-CI.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research